Oral tolerance and pyruvate dehydrogenase in patients with primary biliary cirrhosis

Ayako Suzuki, Judy Van de Water, M. Eric Gershwin, Roberta Jorgensen, Paul Angulo, Keith Lindor

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by the immunological destruction of intralobular bile ducts and serum anti-mitochondrial antibodies (AMA). Based upon previous work of oral tolerance and autoimmunity, we hypothesized that feeding the mitochondrial autoantigens of PBC would alter the clinical course and the level of antimitochondrial antibodies. The bovine pyruvate dehydrogenase complex (PDC) was purified and 5 mg fed in gelatin capsules to 6 patients with early stage PBC for 6 months. Antimitochondrial antibodies and liver biochemistries were measured at every 3 months for 12 months. The clinical trial was completed for all patients except for 1 who showed deterioration of pre-existing skin rash during treatment, which disappeared within 2 weeks after treatment was discontinued. However, after 1 year, neither the titers of AMAs nor liver biochemistries were significantly changed by this treatment. This is the first trial to test the efficacy of oral tolerance induction in PBC. However, the data, which limited in scope, did not demonstrate efficacy and further highlights the difficulties in showing continuing evidence of tolerance induction in autoimmunity.

Original languageEnglish (US)
Pages (from-to)55-61
Number of pages7
JournalDevelopmental Immunology
Volume9
Issue number2
DOIs
StatePublished - Jun 2002
Externally publishedYes

Fingerprint

Biliary Liver Cirrhosis
Pyruvic Acid
Oxidoreductases
Autoimmunity
Biochemistry
Pyruvate Dehydrogenase Complex
Antibodies
Liver
Autoantigens
Gelatin
Exanthema
Bile Ducts
Capsules
Liver Diseases
Anti-Idiotypic Antibodies
Therapeutics
Clinical Trials
Serum

Keywords

  • Antimitochondrial antibodies
  • Autoimmunity
  • Oral tolerance
  • Pyruvate dehydrogenase

ASJC Scopus subject areas

  • Immunology
  • Developmental Biology

Cite this

Oral tolerance and pyruvate dehydrogenase in patients with primary biliary cirrhosis. / Suzuki, Ayako; Van de Water, Judy; Gershwin, M. Eric; Jorgensen, Roberta; Angulo, Paul; Lindor, Keith.

In: Developmental Immunology, Vol. 9, No. 2, 06.2002, p. 55-61.

Research output: Contribution to journalArticle

Suzuki, Ayako ; Van de Water, Judy ; Gershwin, M. Eric ; Jorgensen, Roberta ; Angulo, Paul ; Lindor, Keith. / Oral tolerance and pyruvate dehydrogenase in patients with primary biliary cirrhosis. In: Developmental Immunology. 2002 ; Vol. 9, No. 2. pp. 55-61.
@article{75c7301b35b143a9969bc4769a15fdad,
title = "Oral tolerance and pyruvate dehydrogenase in patients with primary biliary cirrhosis",
abstract = "Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by the immunological destruction of intralobular bile ducts and serum anti-mitochondrial antibodies (AMA). Based upon previous work of oral tolerance and autoimmunity, we hypothesized that feeding the mitochondrial autoantigens of PBC would alter the clinical course and the level of antimitochondrial antibodies. The bovine pyruvate dehydrogenase complex (PDC) was purified and 5 mg fed in gelatin capsules to 6 patients with early stage PBC for 6 months. Antimitochondrial antibodies and liver biochemistries were measured at every 3 months for 12 months. The clinical trial was completed for all patients except for 1 who showed deterioration of pre-existing skin rash during treatment, which disappeared within 2 weeks after treatment was discontinued. However, after 1 year, neither the titers of AMAs nor liver biochemistries were significantly changed by this treatment. This is the first trial to test the efficacy of oral tolerance induction in PBC. However, the data, which limited in scope, did not demonstrate efficacy and further highlights the difficulties in showing continuing evidence of tolerance induction in autoimmunity.",
keywords = "Antimitochondrial antibodies, Autoimmunity, Oral tolerance, Pyruvate dehydrogenase",
author = "Ayako Suzuki and {Van de Water}, Judy and Gershwin, {M. Eric} and Roberta Jorgensen and Paul Angulo and Keith Lindor",
year = "2002",
month = "6",
doi = "10.1080/1044667021000098561",
language = "English (US)",
volume = "9",
pages = "55--61",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Publishing Corporation",
number = "2",

}

TY - JOUR

T1 - Oral tolerance and pyruvate dehydrogenase in patients with primary biliary cirrhosis

AU - Suzuki, Ayako

AU - Van de Water, Judy

AU - Gershwin, M. Eric

AU - Jorgensen, Roberta

AU - Angulo, Paul

AU - Lindor, Keith

PY - 2002/6

Y1 - 2002/6

N2 - Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by the immunological destruction of intralobular bile ducts and serum anti-mitochondrial antibodies (AMA). Based upon previous work of oral tolerance and autoimmunity, we hypothesized that feeding the mitochondrial autoantigens of PBC would alter the clinical course and the level of antimitochondrial antibodies. The bovine pyruvate dehydrogenase complex (PDC) was purified and 5 mg fed in gelatin capsules to 6 patients with early stage PBC for 6 months. Antimitochondrial antibodies and liver biochemistries were measured at every 3 months for 12 months. The clinical trial was completed for all patients except for 1 who showed deterioration of pre-existing skin rash during treatment, which disappeared within 2 weeks after treatment was discontinued. However, after 1 year, neither the titers of AMAs nor liver biochemistries were significantly changed by this treatment. This is the first trial to test the efficacy of oral tolerance induction in PBC. However, the data, which limited in scope, did not demonstrate efficacy and further highlights the difficulties in showing continuing evidence of tolerance induction in autoimmunity.

AB - Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by the immunological destruction of intralobular bile ducts and serum anti-mitochondrial antibodies (AMA). Based upon previous work of oral tolerance and autoimmunity, we hypothesized that feeding the mitochondrial autoantigens of PBC would alter the clinical course and the level of antimitochondrial antibodies. The bovine pyruvate dehydrogenase complex (PDC) was purified and 5 mg fed in gelatin capsules to 6 patients with early stage PBC for 6 months. Antimitochondrial antibodies and liver biochemistries were measured at every 3 months for 12 months. The clinical trial was completed for all patients except for 1 who showed deterioration of pre-existing skin rash during treatment, which disappeared within 2 weeks after treatment was discontinued. However, after 1 year, neither the titers of AMAs nor liver biochemistries were significantly changed by this treatment. This is the first trial to test the efficacy of oral tolerance induction in PBC. However, the data, which limited in scope, did not demonstrate efficacy and further highlights the difficulties in showing continuing evidence of tolerance induction in autoimmunity.

KW - Antimitochondrial antibodies

KW - Autoimmunity

KW - Oral tolerance

KW - Pyruvate dehydrogenase

UR - http://www.scopus.com/inward/record.url?scp=0038415810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038415810&partnerID=8YFLogxK

U2 - 10.1080/1044667021000098561

DO - 10.1080/1044667021000098561

M3 - Article

VL - 9

SP - 55

EP - 61

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

IS - 2

ER -